Profil
Richard Auty has been Chairman of MNLpharma Ltd.
since March 2004.
Prior to joining MNLpharma, he was Director of Research and Development for Zeneca.
Before that Dr. Auty was Director of Drug Development and Research and Development for the Pharmaceutical Division of Fisons Plc.
Previously, he was Non-Executive Director of Cantab Pharmaceuticals Plc from 1997 to 2000 and a Director of the UK Medical Research Council from 1998 to 2000.
Dr. Auty founded Salient Consulting in 1999.
Aktive Positionen von Richard Auty
| Unternehmen | Position | Beginn |
|---|---|---|
MNLpharma Ltd.
 MNLpharma Ltd. Pharmaceuticals: MajorHealth Technology MNLpharma Ltd. develops and sells pharmaceuticals. It offers therapeutic products, research equipment, and related services. The company developed a molecule Immunomodulators for the treatment of cancer, infectious diseases, and immune disorders. It was founded in 1999 and is headquartered in Aberystwyth, UK | Vorsitzender | 01.03.2004 |
Ehemalige bekannte Positionen von Richard Auty
| Unternehmen | Position | Ende |
|---|---|---|
Cantab Pharmaceuticals Plc
 Cantab Pharmaceuticals Plc MiscellaneousMiscellaneous Cantab Pharmaceuticals plc, based in Cambridge, England, was established in 1989 to exploit advances in immunology. Since that time, Cantab has become a leader in the areas of immunotherapy and gene delivery and has developed a broad portfolio of novel products for the treatment and prevention of many chronic infectious diseases, cancer and substance addiction. | Direktor/Vorstandsmitglied | 01.01.2000 |
| UK Medical Research Council | Direktor/Vorstandsmitglied | 01.01.2000 |
Fisons Plc
 Fisons Plc Pharmaceuticals: OtherHealth Technology Fisons Plc Manufactured and supplied ethical and proprietary medicines, veterinary products, laboratory and educational scientific equipment, clinical diagnostic supplies and garden products. The company was headquartered in Ipswichm the United Kingdom. | Corporate Officer/Principal | - |
Zeneca Garden Care
 Zeneca Garden Care Pharmaceuticals: OtherHealth Technology Part of AstraZeneca PLC, Zeneca Garden Care is a British company that develops and manufactures pharmaceutical products, agrochemicals, and specialty chemicals. The company is based in Macclesfield, UK. Zeneca Garden Care was acquired by Zeneca Group Plc on January 01, 1995 for $84.16 million. | Technik-/Wissenschafts-/F&E-Leiter | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 5 |
|---|---|
MNLpharma Ltd.
MNLpharma Ltd. Pharmaceuticals: MajorHealth Technology MNLpharma Ltd. develops and sells pharmaceuticals. It offers therapeutic products, research equipment, and related services. The company developed a molecule Immunomodulators for the treatment of cancer, infectious diseases, and immune disorders. It was founded in 1999 and is headquartered in Aberystwyth, UK | Health Technology |
Zeneca Garden Care
Zeneca Garden Care Pharmaceuticals: OtherHealth Technology Part of AstraZeneca PLC, Zeneca Garden Care is a British company that develops and manufactures pharmaceutical products, agrochemicals, and specialty chemicals. The company is based in Macclesfield, UK. Zeneca Garden Care was acquired by Zeneca Group Plc on January 01, 1995 for $84.16 million. | Health Technology |
Fisons Plc
Fisons Plc Pharmaceuticals: OtherHealth Technology Fisons Plc Manufactured and supplied ethical and proprietary medicines, veterinary products, laboratory and educational scientific equipment, clinical diagnostic supplies and garden products. The company was headquartered in Ipswichm the United Kingdom. | Health Technology |
Cantab Pharmaceuticals Plc
Cantab Pharmaceuticals Plc MiscellaneousMiscellaneous Cantab Pharmaceuticals plc, based in Cambridge, England, was established in 1989 to exploit advances in immunology. Since that time, Cantab has become a leader in the areas of immunotherapy and gene delivery and has developed a broad portfolio of novel products for the treatment and prevention of many chronic infectious diseases, cancer and substance addiction. | Miscellaneous |
| UK Medical Research Council |
